MorningSun trial shows SC mosunetuzumab is effective & well-tolerated for elderly or CIT-ineligible #DLBCL patients. Featuring SCRI’s Dr. Jeff Sharman:
www.hmpgloballearningnetwork.com/site/onc/new... #ASH25 #InnovationInOncology #SCRI
0
0
0
0